Synthesis and Evaluation of the Estrogen Receptor a Selective Radioligand 2-F-18-Fluoro-6-(6-Hydroxynaphthalen-2-y1) Pyridin-3-ol:Comparison with 16 alpha-F-18-Fluoro-17 beta-Estradiol

Estrogen receptors (ERs) are targets for endocrine treatment of estrogen-dependent cancers. The ER consists of 2 isoforms, ER alpha and ER beta, which have distinct biologic functions. Whereas activation of ERa stimulates cell proliferation and cell survival, ER beta promotes apoptosis. PET of ER alpha and ER beta levels could provide more insight in response to hormonal treatment. 16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is a PET tracer for ER with relative selectivity for ER alpha. Here we report the synthesis and evaluation of a potential ER beta-selective PET tracer: 2-F-18-fluoro-6-(6-hydroxynaphthalen-2-yl)pyridin-3-ol (F-18-FHNP). Methods: F-18-FHNP was synthesized by fluorination of the corresponding nitro precursor, followed by acidic removal of the 2-methoxyethoxymethyl protecting group. In vitro affinity of F-18-FHNP and F-18-FES for ER was evaluated in SKOV3 ovarian carcinoma cells. PET imaging and ex vivo biodistribution studies with F-18-FHNP and F-18-FES were conducted in athymic nude mice bearing a SKOV3 xenografts. Results: F-18-FHNP had nanomolar affinity for ERs, with a 3.5 times higher affinity for ER beta. F-18-FHNP was obtained in 15%-40% radiochemical yield (decay-corrected), with a specific activity of 279 +/- 75 GBq/mu mol. F-18-FHNP had a dissociation constant of 2 nM and maximum binding capacity of 18 fmol/10(6) cells, and F-18-FES had a dissociation constant of 3 nM and maximum binding capacity 83 fmol/10(6) SKOV3 cells. Both F-18-FHNP and F-18-FES PET could clearly visualize the tumor in male mice bearing a SKOV3 xenograft. Biodistribution studies showed similar distribution of 18F-FHNP and F-18-FES in most peripheral organs. F-18-FES showed a 2-fold-higher tumor uptake than F-18-FHNP. The tumor-to-plasma ratio of 18F-FES decreased 55% (P = 0.024) and 8% (P = 0.68) when administered in the presence of estradiol (nonselective) and genistein (ER beta-selective), respectively. The tumor-to-plasma ratio of F-18-FHNP decreased 41% (P = 0.004) and 64% (P = 0.0009) when administered with estradiol and genistein, respectively. Conclusion: The new PET tracer F-18-FHNP has suitable properties for imaging and shows relative selectivity for ER beta.